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Estimating the dengue burden in India
Dengue is the most rapidly spreading vector-borne viral 
disease globally, with an increasing number of areas 
at risk.1 Reliable estimates of the burden of dengue are 
important to inform policy and research. However, 
quantifying the true burden globally remains elusive 
because surveillance systems are notoriously poor at 
capturing all symptomatic dengue infections, resulting 
in gross under-reporting. Often higher quality health 
systems have better reporting. Cartographical and 
modelling efforts estimated the global disease burden 
of dengue to amount to 96 million cases in 2010.2 
Samir Bhatt and colleagues2 showed a discrepancy 
between reported versus modelled dengue incidence, 
a discrepancy which was particularly high for India. 
According to their estimates,2 India contributed 34 of 
96 million apparent global dengue infections, a number 
which stands in stark contrast to the 12 484 reported 
cases from India to the WHO in the same year. Such 
a mismatch was also reported for India in another 
study,3 in which the actual number of dengue cases 
were 282 times the number reported by the national 
vector-borne disease control programme. Furthermore, 
a study4 of expatriates living in Delhi, India, had a very 
high incidence of dengue acquired in Delhi, unmasking 
substantial dengue transmission that was not reported 
as such in the local population.
We therefore welcome the well designed, nationally 
representative survey to estimate age-specific 
sero prevalence of dengue infections in India by 
Manoj Murhekar and colleagues published in The Lancet 
Global Health.5 A large study team did a community-
based survey in 240 clusters (118 rural, 122 urban) 
selected from 60 districts of 15 Indian states from 
five geographical regions—a huge undertaking. 
12 300 individuals aged 5–45 years were tested for IgG 
antibodies against the dengue virus with the use of 
indirect ELISA, and catalytic models were constructed to 
estimate force of infection. The overall seroprevalence 
of dengue infection in India was 48·7% (95% CI 
43·5–54·0); increasing from 28·3% (21·5–36·2) among 
children aged 5–8 years to 41·0% (32·4–50·1) among 
children aged 9–17 years and to 56·2% (49·0–63·1) 
among individuals aged 18–45 years. The results are 
quite similar to neighbouring Bangladesh6 but are much 
lower than the seroprevalence in most southeast Asian 
countries where seroprevalence is often documented as 
above 70% already by the age of 9 years.7
The estimated number of dengue infections among 
individuals aged 5–45 years from 30 Indian states 
in 2017 was 12 991 357 (12 825 128–13 130 258) based 
on constant force of infection models. This number 
is lower than Bhatt and colleagues’ modelling study 
(about 13 million based on real seroprevalence data 
vs 34 million based on modelling), but because it is 
based on nationally representative data, Murhekar and 
colleagues’ number is more reliable.
Given the size of and vast geographical differences 
within India, it is not unsurprising that seroprevalence 
differed greatly between regions: the highest sero-
prevalence was in southern regions (76·9%), followed 
by western (62·3%), and northern (60·3%) regions. 
The seroprevalence was also higher for urban (70·9%) 
versus rural areas (42·3%), which is in keeping with the 
observation that urbanisation appears to be one of the 
main drivers for the increase in dengue incidence.6,8 
Urbanisation in India is occurring at a dazzling rate, and 
hence India is poised to see further upsurges of dengue.
Evidence on age-stratified dengue seroprevalence 
is useful for taking informed decisions about the 
introduction of upcoming dengue vaccines in India. 
Several dengue vaccine candidates are in different 
phases of development. The first licensed dengue 
vaccine, CYD-TDV (Dengvaxia), developed by Sanofi 
Pasteur, was only recommended in geographical settings 
with high burden of disease, as indicated by dengue 
seroprevalence of 70% and higher by the age of 9 years;9 
hence India would not meet the criteria for introduction. 
Given the serostatus-dependent performance of 
CYD-TDV,10,11 WHO’s position was further revised in 2018 
to recommend a prevaccination screening strategy 
whereby people are tested for past dengue exposure and 
only those tested seropositive would be vaccinated.9
Murhekar and colleagues provide a true novel 
contribution to the existing knowledge on the dengue 
burden in a subcontinent as vast as India. The study 
was well done with a state-of-the-art research design, 
including modelling the force of infection. Although 
the dengue burden in India at this stage is lower than 
that of most other southeast Asian countries, their data 
show that dengue does pose a substantial public health 
Published Online 
June 11, 2019 
http://dx.doi.org/10.1016/
S2214-109X(19)30249-9
See Articles page e1065
Comment
e989 www.thelancet.com/lancetgh   Vol 7   August 2019
risk. Such evidence should act as an impetus for India 
to invest more in addressing the dengue burden. At the 
same time, it is important to study related flaviviruses, 
such as Zika virus, which could also potentially have a 
devastating effect in India.12
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